SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
Steven Spielberg's 'Disclosure Day' trailer drops: What we know about the alien movie - 2Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- 3Virtual National Science Foundation internships aren’t just a pandemic stopgap – they can open up opportunities for more STEM students
- 4The 15 Most Powerful Forerunners in Business
- 5How we came to be: Scientists get first look at the evolution of early complex animals
- Dominating Your Cash: The Fundamental Manual for Overseeing Individual accounting records
- Polls open in tense Uganda election amid widespread delays
- Good ways to respond if your kid brings home less-than-ideal grades
- Tesla plans to expand production at German car plant
- Hundreds are quarantined in South Carolina as measles spreads in 2 US outbreaks
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- Step by step instructions to Safeguard Your Teeth During Sports Exercises
- Amateur's Manual for Venture Strategies for Tenderfoots
- Tatiana Schlossberg's diagnosis puts spotlight on leukemia: What to know
